Comparison of clinical characteristics of patients with AH-MCL (blastoid vs pleomorphic MCL), including all patients, AH-DN, and AH-t
| Characteristic . | Blastoid (n = 152) . | Pleomorphic (n = 31) . | P . |
|---|---|---|---|
| Age, median (range), y | 65 (31-95) | 65 (39-85) | .46 |
| Sex, male/female, n (%) | 113 (74)/39 (26) | 24 (77)/7 (23) | .71 |
| AH-MCL category, n (%) | |||
| AH-DN/AH-t | 93 (61)/59 (39) | 15 (48)/16 (52) | .18 |
| PS-ECOG, n (%) | .51 | ||
| 0 | 30 (20) | 10 (32) | |
| 1 | 87 (58) | 16 (52) | |
| 2 | 24 (16) | 3 (10) | |
| 3 | 4 (3) | 1 (3) | |
| 4 | 5 (3) | 1 (3) | |
| B symptoms, yes/no, n (%) | 30 (20)/121 (80) | 5 (17)/26 (83) | .63 |
| Leukemic phase, yes/no, n (%) | 43 (28)/108 (72) | 6 (20)/24 (80) | .34 |
| Bone marrow involved by MCL, yes/no, n (%) | 93 (69)/41 (31) | 13 (52)/12 (48) | .09 |
| CNS involvement, yes/no, n (%) | 5 (3)/147 (97) | 3 (10)/28 (90) | .136 |
| Light chain type, κ/λ, n (%) | 74 (59)/51 (41) | 16 (67)/8 (33) | .49 |
| Ki-67, median (range), % | 70 (10-100) | 70 (30-100) | .76 |
| LDH above the ULN, yes/no, median (range), IU/L | 68 (46)/80 (54) | 11 (41)/16 (59) | .61 |
| SOX-11 expression (±), n (%) | 23 (77)/7 (23) | 7 (100)/0 (0) | .30 |
| WBC, median (range), 103/µL | 6 (1-205) | 6 (2-98) | .71 |
| Serum LDH, median (range), IU/L | 581 (202-42 000) | 564 (314-5122) | .82 |
| Serum β2-microglobulin, median (range), mg/dL | 3 (1-19) | 3 (2-12) | .57 |
| Hemoglobin, median (range), g/dL | 12 (7-16) | 12 (7-15) | .94 |
| Platelet count, median (range), 103/µL | 162 (8-500) | 171 (12-615) | .56 |
| Absolute monocyte count, median (range), 103/µL | 0.56 (0.07-25) | 0.62 (0.17-5) | .08 |
| Absolute lymphocyte count, median (range), 103/µL | 1 (0.10-75) | 1 (0.16-78) | .74 |
| First-line treatments, n (%) | .138 | ||
| R-HCVAD based | 48 (36) | 11 (39) | |
| R-HCVAD based and SCT consolidation | 14 (10) | 0 (0) | |
| R-chemotherapy | 32 (24) | 5 (18) | |
| R-chemotherapy and SCT consolidation | 7 (5) | 0 (0) | |
| R-lenalidomide with/without other agents | 6 (4) | 2 (7) | |
| R-lenalidomide with/without other agents and SCT | 0 (0) | 1 (4) | |
| Ibrutinib/other BTK inhibitor | 11 (8) | 5 (18) | |
| Ibrutinib/other BTK inhibitor and SCT consolidation | 3 (2) | 0 (0) | |
| Miscellaneous | 14 (10) | 4 (14) | |
| Response to first-line treatment, CR/no CR, n (%) | 76 (57)/58 (43) | 14 (50)/14 (50) | .51 |
| Characteristic . | Blastoid (n = 152) . | Pleomorphic (n = 31) . | P . |
|---|---|---|---|
| Age, median (range), y | 65 (31-95) | 65 (39-85) | .46 |
| Sex, male/female, n (%) | 113 (74)/39 (26) | 24 (77)/7 (23) | .71 |
| AH-MCL category, n (%) | |||
| AH-DN/AH-t | 93 (61)/59 (39) | 15 (48)/16 (52) | .18 |
| PS-ECOG, n (%) | .51 | ||
| 0 | 30 (20) | 10 (32) | |
| 1 | 87 (58) | 16 (52) | |
| 2 | 24 (16) | 3 (10) | |
| 3 | 4 (3) | 1 (3) | |
| 4 | 5 (3) | 1 (3) | |
| B symptoms, yes/no, n (%) | 30 (20)/121 (80) | 5 (17)/26 (83) | .63 |
| Leukemic phase, yes/no, n (%) | 43 (28)/108 (72) | 6 (20)/24 (80) | .34 |
| Bone marrow involved by MCL, yes/no, n (%) | 93 (69)/41 (31) | 13 (52)/12 (48) | .09 |
| CNS involvement, yes/no, n (%) | 5 (3)/147 (97) | 3 (10)/28 (90) | .136 |
| Light chain type, κ/λ, n (%) | 74 (59)/51 (41) | 16 (67)/8 (33) | .49 |
| Ki-67, median (range), % | 70 (10-100) | 70 (30-100) | .76 |
| LDH above the ULN, yes/no, median (range), IU/L | 68 (46)/80 (54) | 11 (41)/16 (59) | .61 |
| SOX-11 expression (±), n (%) | 23 (77)/7 (23) | 7 (100)/0 (0) | .30 |
| WBC, median (range), 103/µL | 6 (1-205) | 6 (2-98) | .71 |
| Serum LDH, median (range), IU/L | 581 (202-42 000) | 564 (314-5122) | .82 |
| Serum β2-microglobulin, median (range), mg/dL | 3 (1-19) | 3 (2-12) | .57 |
| Hemoglobin, median (range), g/dL | 12 (7-16) | 12 (7-15) | .94 |
| Platelet count, median (range), 103/µL | 162 (8-500) | 171 (12-615) | .56 |
| Absolute monocyte count, median (range), 103/µL | 0.56 (0.07-25) | 0.62 (0.17-5) | .08 |
| Absolute lymphocyte count, median (range), 103/µL | 1 (0.10-75) | 1 (0.16-78) | .74 |
| First-line treatments, n (%) | .138 | ||
| R-HCVAD based | 48 (36) | 11 (39) | |
| R-HCVAD based and SCT consolidation | 14 (10) | 0 (0) | |
| R-chemotherapy | 32 (24) | 5 (18) | |
| R-chemotherapy and SCT consolidation | 7 (5) | 0 (0) | |
| R-lenalidomide with/without other agents | 6 (4) | 2 (7) | |
| R-lenalidomide with/without other agents and SCT | 0 (0) | 1 (4) | |
| Ibrutinib/other BTK inhibitor | 11 (8) | 5 (18) | |
| Ibrutinib/other BTK inhibitor and SCT consolidation | 3 (2) | 0 (0) | |
| Miscellaneous | 14 (10) | 4 (14) | |
| Response to first-line treatment, CR/no CR, n (%) | 76 (57)/58 (43) | 14 (50)/14 (50) | .51 |